Why Invest in NIH Research? | UMR Offers
Fact Sheets Explaining Why Congress Must #keepNIHstrong
Mark Your Calendars! | UMR's 2025 Annual Report is Coming Soon!
Rural State Analysis | UMR's 2023 Report Reveals the Exponential Impact of NIH Research Funding in 7 Rural States
Why Invest in NIH Research? | UMR Offers
Fact Sheets Explaining Why Congress Must #keepNIHstrong
Mark Your Calendars! | UMR's 2025 Annual Report is Coming Soon!
Rural State Analysis | UMR's 2023 Report Reveals the Exponential Impact of NIH Research Funding in 7 Rural States
Why Invest in NIH Research? | UMR Offers
Fact Sheets Explaining Why Congress Must #keepNIHstrong
Low on antibodies, blood cancer patients can fight off COVID-19 with T cells
Antibodies aren’t the only immune cells needed to fight off COVID-19—T cells are equally important and can step up to do the job when antibodies are depleted, suggests a new Penn Medicine study of blood cancer patients with COVID-19 published in Nature Medicine. The researchers found that blood cancer patients with COVID-19 who had higher CD8 T cells, many of whom had depleted antibodies from cancer treatments, were more than three times likelier to survive than patients with lower levels of CD8 T cells.